Physician profile
Kevin M Daus
NPI 1386732048
$1,826.19
in general payments reported to CMS, 2019-2025
14 companies · $18.94 in 2025
The $18.94 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $130 · 2021: $511 · 2022: $618 · 2023: $415 · 2025: $18.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.27 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $581.98 | 2019-2023 | Wegovy, Saxenda |
| Abbvie INC. | $196.46 | 2020-2023 | Orilissa |
| Scynexis, INC. | $186.88 | 2021-2022 | |
| Astellas Pharma US INC | $153.38 | 2023-2025 | Veozah, Myrbetriq |
| Evofem Biosciences, INC. | $122.66 | 2021-2023 | Phexxi |
| Myovant Sciences INC. | $116.96 | 2021-2022 | |
| Pfizer INC. | $105.38 | 2022-2023 | |
| Daiichi Sankyo INC. | $88.22 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $75.99 | 2023 | Myfembree |
| Therapeuticsmd, INC. | $75.18 | 2020-2022 | |
| Mycovia Pharmaceuticals, INC. | $50.42 | 2023 | Vivjoa |
| Agile Therapeutics, INC. | $32.86 | 2022 | |
| Currax Pharmaceuticals LLC | $27.66 | 2020-2022 | |
| Coopersurgical, INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Daus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.